Immunovant Inc
IMVT
Get informed when a big investor buys or sells
+ FollowMarket Cap$5.87B
Close$
$4.94
82.6% downside
Current Fair Value
82.6% downsideOvervalued by 82.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.87 Billion |
|---|---|
| Enterprise Value | $5.07 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.77 |
| Beta | 0.84 |
| Outstanding Shares | 205,545,373 |
Return
| Return on Equity | -73.19% |
|---|---|
| Return on Assets | -63.13% |
| Return on Invested Capital | -60.45% |
Valuation & Multiples
| P/E Ratio | -10.07 |
|---|---|
| PEG | -37.26 |
| Price to Sales | - |
| Price to Book Ratio | 9.47 |
| Enterprise Value to Revenue | 714.64 |
| Enterprise Value to EBIT | -11.41 |
| Enterprise Value to Net Income | -10 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-0.60
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 9, 2026
EPS Estimate
$-0.74
Average shareholder expectationRevenue Estimate
$7.09 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 15.36% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 2.35%▼ 51.68% |
|---|---|
| Total Invested | $163.49M▼ 96.18% |
| Investors Holding | 23▼ 217.00% |
ESG Score
No data